Hikma launches mitomycin for injection
Hikma Pharmaceuticals has launched mitomycin for injection in 20-mg and 40-mg dosage strengths.
Hikma’s mitomycin for injection is indicated to treat disseminated adenocarcinoma of the stomach or pancreas in proven combination with other chemotherapy drugs, and as palliative treatment when other treatments have failed.
Mitomycin for injection had a market value of approximately $43 million in the 12 months ended November 2018, according to IQVIA.
“We are excited to add mitomycin for injection to our oncology portfolio in the U.S., improving patients’ access to this important medicine,” Riad Mechlaoui, Hikma's president of injectables, said. “This demonstrates the successful execution of our strategy to expand our portfolio in key therapeutic areas.”
Hikma’s mitomycin for injection is indicated to treat disseminated adenocarcinoma of the stomach or pancreas in proven combination with other chemotherapy drugs, and as palliative treatment when other treatments have failed.
Mitomycin for injection had a market value of approximately $43 million in the 12 months ended November 2018, according to IQVIA.
“We are excited to add mitomycin for injection to our oncology portfolio in the U.S., improving patients’ access to this important medicine,” Riad Mechlaoui, Hikma's president of injectables, said. “This demonstrates the successful execution of our strategy to expand our portfolio in key therapeutic areas.”